Jabbit

Peptides and the Compounding List: What Might Change Next

A live explainer for patients tracking peptide access, policy shifts, and practical next steps.

This article is for informational purposes only and is not medical advice. For personal guidance about any medication or treatment, consult a licensed healthcare professional.

🆕 Latest (updated Oct 30, 2026): On October 14, 2026, the White House regulatory review office (OIRA, part of the Office of Management and Budget) received an FDA document titled “Interim Access Policy for Compounding Using Certain Peptides” (RIN 0910-ZD94). OIRA finished its review on October 27, 2026, coded “Consistent with Change,” which means something in the document changed during review (OIRA: reviews completed in the last 30 days). At 11:15 AM ET on October 28, 2026, HHS filed it for public inspection as “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,” and it was published in the Federal Register on October 30, 2026 (Federal Register: FR Doc. 2026-22192, 91 FR 68526). Its Appendix A lists six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. HHS says it does not intend to take enforcement action against 503A pharmacies that compound them under its conditions; the notice calls the document a draft open to comment on regulations.gov (Docket No. HHS-OASH-2026-0496) until 2 weeks after publication, with regulations.gov listing a November 13, 2026 deadline, and it does not add these peptides to the 503A bulks list (HHS policy text). OIRA’s meeting list for this document shows four meetings requested by outside groups: the American Academy of Peptide Medicine (Oct 21), Hims & Hers Health (Oct 23), the Alliance for Pharmacy Compounding (Oct 27) and the Center for Science in the Public Interest (Oct 27) (OIRA meeting list). What news reports say the policy may do, and what FDA’s own reviewers found on BPC-157 and other peptides, is in our FDA peptide compounding policy explainer; the meetings are covered in who is meeting the White House about it. For where each peptide stands, peptide by peptide, see our FDA peptide status tracker.

First: What “the compounding list” usually means

Most conversations about U.S. compounding policy reference FDA pathways tied to 503A/503B compounding and related shortage/eligibility frameworks. In plain language: if a drug substance or product category is restricted, shortages resolve, or policy interpretation shifts, compounding availability can change quickly.

Primary references:

What’s being discussed right now

There are public comments and political statements suggesting tighter oversight for certain compounded peptide products. Statements alone are not final policy. What matters for access is formal action (published guidance, enforcement updates, shortage status changes, or finalized rulemaking).

Important: A headline can move faster than regulation. Before acting, verify whether there is a new official FDA publication that directly changes compounding status.

What could change if policy tightens

  • Availability swings: Some compounded peptide options may become harder to obtain.
  • Price volatility: Supply contractions can push prices up in the short term.
  • Pharmacy variance: Some pharmacies may change what they dispense faster than others based on legal/compliance posture.
  • More verification burden: Patients may need to confirm sourcing, lot details, and pharmacy credentials more frequently.

What to watch (signal over noise)

  1. FDA source docs (not social clips alone)
  2. Drug shortage status changes for related products
  3. Official pharmacy communications describing any dispensing changes
  4. Timing details (effective dates, transition windows, enforcement timelines)

Practical checklist for patients

  • Keep your current medication history and fill timeline organized.
  • Save lot/label photos for each fill in case you need to verify product details later.
  • Confirm with your prescriber/pharmacy what alternatives exist if access changes.
  • Track side effects and outcomes consistently so treatment discussions are evidence-based.

Our update policy for this page

As new information breaks, we will append a dated changelog below with:

  • What changed
  • Which official source confirms it
  • What it likely means operationally for patients

No official source, no definitive claim.

Changelog

  • 2026-10-30 (about 4 AM ET): HHS’s peptide policy notice was published in the Federal Register on October 30, 2026 (91 FR 68526). Updated the note at the top and the source links, and added how to comment: the notice says written comments can be submitted on regulations.gov (Docket No. HHS-OASH-2026-0496) until 2 weeks after publication, and regulations.gov lists the comment deadline as November 13, 2026, 11:59 PM ET. Source: Federal Register: FR Doc. 2026-22192, 91 FR 68526.
  • 2026-10-28 (about noon ET): Updated the note at the top: HHS filed the interim peptide policy for public inspection at 11:15 AM ET, for Federal Register publication on October 30; it lists BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Sources: Federal Register: FR Doc. 2026-22192, 91 FR 68526; HHS policy text.
  • 2026-10-28 (about 10 AM ET): Updated the note at the top: OIRA concluded its review of the interim peptide policy on October 27, 2026, “Consistent with Change”; as of about 10 AM ET on October 28 the text was not in the Federal Register, and OIRA’s meeting list showed four meetings. Sources: OIRA: reviews completed in the last 30 days; OIRA: EO 12866 meetings for RIN 0910-ZD94.
  • 2026-10-24: Linked our new FDA peptide status tracker, a sourced table of where 21 peptides and NAD+ stand with FDA. The interim policy was still listed as pending at OIRA on October 24, 2026.
  • 2026-10-21: Replaced the April note at the top with the October 2026 status: FDA’s “Interim Access Policy for Compounding Using Certain Peptides” (RIN 0910-ZD94) was received for White House review on October 14, 2026, and was still listed as pending on October 21, 2026, at about 3:55 PM ET; OIRA lists three requested meetings on it (Oct 21, Oct 23, Oct 27). Sources: OIRA: pending EO 12866 review, RIN 0910-ZD94; OIRA: EO 12866 meetings for RIN 0910-ZD94.
  • 2026-04-18: Noted that FDA’s Drug Shortages database index view lists liraglutide injection as “Currently in Shortage,” while FDA’s GLP-1 compounding policy clarification states semaglutide and tirzepatide “do not currently appear” on the FDA drug shortage list (as of the statement on that page). Sources: FDA Drug Shortages database (index); FDA: clarifies policies for compounders as national GLP-1 supply begins to stabilize.
  • 2026-04-17: Added additional specifics from FDA’s 2026-04-01 GLP-1 compounding clarification, including (a) an explicit example that semaglutide + another API (for example vitamin B12) can still be treated as “essentially a copy” absent documented “significant difference” for an identified patient, and (b) FDA’s reiterated non-action policy language around “four or fewer prescriptions per month” for products compounded “regularly or in inordinate amounts.” Source: FDA: clarifies policies for compounders as national GLP-1 supply begins to stabilize.
  • 2026-04-13: Added FDA policy clarification page (dated 2026-04-01) about compounding conditions under 503A/503B, including discussion of “essentially a copy” (with a GLP-1 example where adding another API, for example vitamin B12, may still be considered a copy when route/strength are easily substitutable) and the role of the 503B bulks list and the drug shortage list. The same page also states semaglutide and tirzepatide “do not currently appear” on the 503B bulks list or the FDA drug shortage list (as of the page’s statement). Sources: FDA: clarifies policies for compounders as national GLP-1 supply begins to stabilize; FDA: Bulk drug substances used in compounding; FDA: Human drug compounding laws.
  • 2026-04-13: Added FDA Warning Letter source (dated 2026-03-31) to Prime Sciences regarding marketing/selling GLP-1 related “research” peptides as unapproved new drugs, reinforcing FDA’s enforcement posture around weight-loss/diabetes claims and injectable use. Source: Prime Sciences.
  • 2026-04-11: Added FDA Warning Letter sources (dated 2026-03-31) involving online sales of tirzepatide and retatrutide marketed as “research peptides,” including FDA’s stated public-health concern about injectable products and its view that selling bacteriostatic water alongside these products indicates intended human injection use. Sources: Lovega LLC dba Pink Pony Peptides; Gram Peptides.
  • 2026-02-28: Initial publication. Baseline explainer + monitoring framework created.
  • 2026-02-28 (later): Added source watch item for Joe Rogan Experience #2461 with Robert F. Kennedy Jr.. At time of update, we have not found an official transcript segment confirming a formal new peptide-compounding rule text. We will append exact quote + timestamp if/when transcript evidence is published.

Disclaimer: This content is informational only and does not replace individualized medical, legal, or regulatory guidance. Always verify policy changes via official agency publications and speak with a licensed healthcare professional before making treatment decisions.